Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-02
2011-08-02
Andres, Janet (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S316000
Reexamination Certificate
active
07989629
ABSTRACT:
The present invention relates to a compound of formula (I), or a salt thereofwherein the naphthalene ring is substituted in the 2, 3, 4, 5, 6, 7 or 8 position by R1, and R1represents —CH2CH2COOH or —CH═C(CH3)COOH, and to processes for their preparation, to compositions containing them and to their use in the treatment of various inflammatory and/or allergic diseases, such as diseases such as allergic rhinitis.
REFERENCES:
patent: 7465795 (2008-12-01), Chapdelaine et al.
patent: 2004/035556 (2004-04-01), None
patent: 2004/037800 (2004-05-01), None
patent: 2004/089373 (2004-10-01), None
patent: 2005116037 (2005-12-01), None
patent: 2007/122156 (2007-11-01), None
Scadding, G. “Predicting and Establishing the Clinical Efficacy of a Histamine H1-Receptor Antagonist” Clinical Drug Investigation Mar. 1, 2005 25(3), 153-164.
Simons, F. “Antihistamines” Middleton's Allergy: Principles and Practice Sixth edition. Chapter 51: 834-863, 2003.
Grant R. Zimmermann “Multi-target therapeutics: when the whole is greater than the sum of the parts.” Drug Discovery Today 2007, 12, 34-42.
Borisy et. al. “Systematic discovery of multicomponent therapeutics” PNAS 2003, 100, 7977-7982.
Sylvain Celanier, Maikel Wijtmans, Patrice Talaga, Rob Leurs, Iwan J. P. De Esch; Histamine H3 receptor Antagonists reach out for the clinic; Drug Discovery Today; Dec. 2005; 10; 1613-1627; Elsevier Science Ltd; London, UK.
McLeod et al.; “Effect of combined histamine H1 and H3 receptor blockade on cutaneous microvascular permeability elicited by compound 48/80”; Life Sciences; 2005; vol. 76, No. 16; pp. 1787-1794; Pergamon Press; Oxford, GB.
Hodgson Simon Teanby
Procopiou Panayiotis Alexandrou
Vinader Brugarolas Maria Victoria
Andres Janet
Glaxo Group Limited
O'Dell David K
Riek James P.
LandOfFree
3-(4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] oxy}... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-(4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] oxy}..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] oxy}... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2739296